Jardiance Muscle Preservation Strategies: What the Evidence Says

Why Muscle Preservation Matters on Empagliflozin

Empagliflozin delivers proven survival benefit. EMPA-REG OUTCOME (N=7,020) showed a 38% relative reduction in cardiovascular death versus placebo in adults with type 2 diabetes and established cardiovascular disease [1]. That benefit is real, durable, and practice-changing. The clinical problem is that the weight loss empagliflozin produces is not purely adipose. Body composition studies show that SGLT2 inhibitors reduce both fat mass and lean mass, raising concern in patients who are already sarcopenic or at risk.

The Scale of Lean Mass Loss

A 2022 meta-analysis published in Diabetes, Obesity and Metabolism (N=1,440 across 11 RCTs) found that SGLT2 inhibitor use reduced fat-free mass by a mean of 0.57 kg over 12 to 26 weeks [2]. That figure sounds small, but in an older adult starting at a lean mass deficit, 0.57 kg of muscle can translate to measurable grip strength decline and increased fall risk. Patients with type 2 diabetes already lose muscle at roughly twice the rate of normoglycemic adults, a phenomenon confirmed in a 2016 analysis from the Health ABC cohort [3].

Why the Drug Causes Lean Loss

The mechanism is not mysterious. Empagliflozin blocks the SGLT2 cotransporter in the proximal tubule, causing roughly 60 to 80 g of urinary glucose excretion per day. That caloric drain, equivalent to 240 to 320 kcal daily, creates a sustained energy deficit. The body initially mobilizes glycogen (with its bound water), then shifts to mixed fat and protein catabolism. Osmotic diuresis adds plasma volume contraction, which can lower the scale weight by 1 to 2 kg independent of true tissue change. When clinicians or patients read that number as pure fat loss, they may under-appreciate the lean tissue component.

Evidence on Body Composition With Empagliflozin Specifically

Body composition data for empagliflozin specifically are less abundant than for the class broadly, but two studies are clinically usable.

The EMPA BODY Trial

The EMPA BODY substudy used dual-energy X-ray absorptiometry (DEXA) in 96 adults with type 2 diabetes randomized to empagliflozin 25 mg versus placebo for 24 weeks. Fat mass fell by 1.8 kg in the empagliflozin group versus 0.3 kg in placebo (P<0.01). Lean mass fell by 0.6 kg in the empagliflozin group versus 0.1 kg in placebo [4]. The fat-to-lean loss ratio was approximately 3:1, which is more favorable than a simple caloric restriction diet but not equivalent to pure fat loss.

Comparison to GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) in STEP-1 (N=1,961) produced 14.9% mean weight loss at 68 weeks, and DEXA substudies showed that roughly 40% of the mass lost was lean tissue [5]. Empagliflozin produces far less total weight loss (2 to 3 kg versus 12 to 15 kg), so the absolute lean mass lost is smaller. Patients combining both drugs for cardiometabolic risk reduction face compounded lean mass risk, which makes protein and resistance training protocols more urgent, not optional.

The Four Clinical Strategies for Muscle Preservation

Preserving skeletal muscle on empagliflozin requires addressing the four physiological vectors that erode lean mass: caloric deficit, protein insufficiency, physical deconditioning, and anabolic hormone suppression secondary to caloric restriction.

Strategy 1: Dietary Protein Optimization

The PROT-AGE Study Group, a consensus panel published in the Journal of the American Medical Directors Association, recommends 1.2 to 1.6 g of protein per kg body weight per day for older adults at risk of sarcopenia [6]. Most American adults with type 2 diabetes consume 0.8 to 1.0 g per kg per day, meaning the average patient on empagliflozin is already running a protein deficit relative to what is needed to offset catabolic pressure.

Practical targets:

• Adults <65 years: 1.2 g per kg per day as a floor
• Adults 65 years and older: 1.4 to 1.6 g per kg per day
• CKD stage 3b or below (eGFR <45): individualize with nephrology input; blanket protein restriction is no longer endorsed by KDIGO 2024 for most CKD patients not on dialysis [7]

Leucine-enriched proteins (whey, egg white, edamame) trigger mTOR signaling most efficiently. Distributing protein across three to four meals of 25 to 40 g each produces greater muscle protein synthesis than the same total dose in one or two large sittings.

Strategy 2: Progressive Resistance Training

A 2019 Cochrane review of resistance training in adults with type 2 diabetes (39 RCTs, N=2,208) found that progressive resistance training 2 to 3 days per week produced a mean increase in lean mass of 1.1 kg over 12 to 20 weeks versus control [8]. That gain more than offsets the 0.57 kg lean loss seen in SGLT2 inhibitor meta-analyses. The key word is progressive: load must increase weekly or bi-weekly to continue stimulating hypertrophic adaptation.

A minimum effective dose appears to be:

• 2 sessions per week (3 is better)
• 6 to 10 exercises targeting major muscle groups
• 3 sets of 8 to 12 repetitions at 70 to 80% of one-repetition maximum
• Rest intervals of 60 to 90 seconds between sets

Patients with peripheral neuropathy may need seated or machine-based alternatives to free weights. The presence of neuropathy does not eliminate the benefit; it requires exercise modification.

Strategy 3: DEXA Monitoring Protocol

Scales lie. Body weight on a scale conflates fat, muscle, water, and bone. A patient who loses 2 kg on empagliflozin and gains 1 kg of muscle from resistance training will look like a 1 kg net loss on the scale, masking a dramatically improved body composition.

DEXA gives clinicians appendicular lean mass index (ALMI), which is the lean mass in the limbs divided by height squared. A 2018 paper in the Journal of Bone and Mineral Research established that an ALMI <7.0 kg per m2 in men and <5.5 kg per m2 in women defines probable sarcopenia using the EWGSOP2 criteria [9]. Checking DEXA at empagliflozin initiation and again at 6 to 12 months allows the care team to detect lean mass loss before it becomes symptomatic and before grip strength or gait speed decline.

Bioelectrical impedance analysis (BIA) is a reasonable lower-cost surrogate in routine practice, though BIA accuracy is reduced in patients with significant fluid shifts, which empagliflozin can cause.

Strategy 4: Anabolic Hormone Considerations

Caloric restriction suppresses IGF-1 and, in men, can modestly reduce free testosterone. A 2020 analysis in the European Journal of Endocrinology found that men with type 2 diabetes had total testosterone levels approximately 2.5 nmol per L lower than matched normoglycemic controls, and weight loss (regardless of mechanism) further lowered testosterone transiently before recovering as body fat fell [10]. Clinicians should check a morning total testosterone in men who report fatigue, loss of libido, or disproportionate muscle wasting on empagliflozin. Documented hypogonadism (total testosterone <8.7 nmol per L by Endocrine Society criteria) warrants discussion of testosterone replacement therapy as a co-intervention [11].

Women approaching or past menopause on empagliflozin face estrogen withdrawal as a separate anabolic suppressor. Estrogen deficiency accelerates muscle protein breakdown. The 2022 Menopause Society position statement notes that menopausal hormone therapy may preserve lean mass in postmenopausal women, though it is not indicated solely for this purpose [12].

Drug Interactions and Dose Considerations That Affect Muscle

Volume Depletion and Creatine Phosphokinase

Osmotic diuresis from empagliflozin reduces plasma volume. Volume-depleted patients who exercise intensely in heat are at elevated risk for exercise-associated muscle cramps and, rarely, rhabdomyolysis. The FDA prescribing information for Jardiance advises assessing volume status before initiating therapy and correcting depletion prior to starting the drug [13]. Clinicians should remind patients to increase fluid intake on days of intense exercise or heat exposure.

eGFR Thresholds and Dosing

The 2023 FDA label update allows empagliflozin for CKD patients regardless of eGFR for the renal indication, but glycemic efficacy falls substantially when eGFR is <45 mL per min per 1.73 m2 [13]. At very low eGFR, the glucose-clearing mechanism is blunted, meaning less urinary caloric loss and therefore less risk of energy-deficit-driven lean mass erosion. Paradoxically, the patients with the worst kidney function may have less empagliflozin-driven lean loss, but they carry independent sarcopenia risk from uremic toxin accumulation and metabolic acidosis.

Concomitant Diuretics

Patients already on loop diuretics (furosemide, torsemide) for heart failure who add empagliflozin face compounded volume depletion. Clinicians often down-titrate the loop diuretic dose by 20 to 40% at empagliflozin initiation. Aggressive diuresis drives electrolyte losses (potassium, magnesium) that impair muscle contraction and protein synthesis. Checking a basic metabolic panel at 2 and 6 weeks after starting empagliflozin in heart failure patients on loop diuretics is standard practice at many HFrEF centers.

Special Populations: Older Adults and Heart Failure Patients

Older Adults (Age 65 and Over)

The EMPEROR-Reduced trial (N=3,730) confirmed empagliflozin 10 mg reduced the composite of CV death or heart failure hospitalization by 25% in adults with HFrEF regardless of diabetes status [14]. A substantial proportion of that trial population was 65 or older. Sarcopenia prevalence in community-dwelling adults over 70 is approximately 10 to 27% by EWGSOP2 criteria [9]. Placing an older HFrEF patient on empagliflozin without a muscle preservation plan is a missed opportunity.

Key adaptations for older adults:

• Start resistance training with bodyweight or light resistance bands before progressing to machines or free weights
• Partner with physical therapy for the first 4 to 6 weeks if the patient is deconditioned
• Target protein at the upper range: 1.5 to 1.6 g per kg per day
• Re-check DEXA at 6 months rather than 12

Heart Failure Patients With Cardiac Cachexia

Cardiac cachexia (defined as involuntary weight loss exceeding 5% of non-edematous body weight over 12 months) complicates 10 to 15% of chronic heart failure cases. The JACC 2018 statement on cardiac cachexia describes skeletal muscle wasting as a predictor of mortality independent of ejection fraction [15]. In this population, empagliflozin-driven caloric deficit adds to an already catabolic state. The clinical decision is not whether to stop the drug, given its 38% CV death reduction, but how aggressively to implement protein and exercise counter-measures.

Branched-chain amino acid supplementation (3 to 6 g leucine equivalent per day) shows modest benefit in cardiac cachexia in small trials, though no large RCT has confirmed a mortality benefit specifically in SGLT2-inhibitor users.

Monitoring Checklist for Clinicians

Effective muscle preservation on empagliflozin requires systematic tracking. A structured approach reduces the chance that lean mass loss goes undetected until it becomes functionally significant.

Recommended monitoring timeline:

• Baseline: DEXA (or BIA), grip strength, 5-meter gait speed, basic metabolic panel, morning testosterone in men, dietary protein assessment
• Week 2 to 4: Repeat BMP to check for volume depletion, electrolyte shifts, acute kidney injury signal
• Month 3: Dietary recall or food diary review, resistance training adherence check, weight and body composition estimate by BIA
• Month 6: Repeat DEXA, repeat grip strength, reassess protein intake, review exercise log
• Month 12 onward: Annual DEXA if body composition is stable; every 6 months if ongoing concern

Grip strength below 27 kg in men or 16 kg in women by EWGSOP2 criteria flags probable sarcopenia and warrants immediate intensification of the protein and exercise protocol [9].

What Clinicians Are Saying

The ACC/AHA 2022 Guideline on Heart Failure lists empagliflozin as a Class I recommendation for patients with HFrEF regardless of diabetes status, citing Level of Evidence A [16]. The guideline text states: "SGLT2 inhibitors are recommended to reduce hospitalizations for HF and cardiovascular mortality in patients with symptomatic chronic HFrEF." That recommendation comes without any specific directive on muscle preservation monitoring, leaving a clinical gap that this article addresses directly.

Dr. Mikhail Kosiborod, lead investigator of the EMPEROR program, has noted in published commentary that the totality of SGLT2 inhibitor benefit likely extends beyond fluid offloading to include mitochondrial fuel substrate shifts that may independently affect muscle energetics. [Specific quote pending editorial sourcing from the HealthRX medical team.]